Results 61 to 70 of about 3,126,313 (204)

Development and validation of a model for the early prediction of progression from essential thrombocythemia to post-essential thrombocythemia myelofibrosis: a multicentre retrospective studyResearch in context

EClinicalMedicine
Summary: Background: Essential thrombocythemia (ET), a myeloproliferative neoplasm (MPN), has a substantial risk of evolving into post-essential thrombocythemia myelofibrosis (post-ET MF).
Danhong Xiang, Xiudi Yang, Honglan Qian, Li Zhang, Yanxia Han, Yongcheng Sun, Ying Lu, Yu Chen, Dan Cao, Meiwei Hu, Lifeng Wang, Qinli Tang, Dijiong Wu, Guoyan Tian, Hongyan Tong, Jie Jin, Jian Huang   +16 more
doaj   +1 more source

Neurological disorders in essential thrombocythemia

Haematologica, 2011
Patients with essential thrombocythemia often complain of various subjective neurological symptoms. This prospective study aims to assess their incidence and response to therapy.
Segolene Billot, Eirini G. Kouroupi, Johan Le Guilloux, Bruno Cassinat, Caroline Jardin, Thierry Laperche, Pierre Fenaux, Antoine F. Carpentier, Jean-Jacques Kiladjian   +8 more
doaj   +1 more source

One thousand patients with essential thrombocythemia: the Mayo Clinic experience

Blood Cancer Journal
We describe 1000 patients with essential thrombocythemia seen at the Mayo Clinic between 1967 and 2023: median age 58 years (18–90), females 63%, JAK2/CALR/MPL-mutated 62%/27%/3%, triple-negative (TN) 8%, extreme thrombocytosis (ExT; platelets ≥1000 ...
N. Gangat, Omer S Karrar, A. Al-Kali, K. Begna, M. Elliott, A. Wolanskyj-Spinner, A. Pardanani, C. Hanson, R. Ketterling, A. Tefferi   +9 more
semanticscholar   +1 more source

Targeting DESI2 as a Novel Therapeutic Strategy for JAK2‐Mutant Leukemias

Advanced Science, EarlyView.
Mass spectrometry‐based proteomics identify DESI2 as a novel component of the JAK2‐V617F complex, which associates with and stabilizes mutant JAK2 through deSUMOylation and deubiquitination, therefore promoting JAK2 mutant cell growth and MPN disease onset in vivo.
Husheng Mei, Wuqiang Wen, Wenjun Zhang, Shujing Zhang, Ting Sun, Guiming Li, Jing Zhang, Shuang Qi, Jie Zhou, Bing Li, Yunshuo Zhao, Xiaotong Chen, Bowen Li, Yiying Xue, Wang Lu, Yanli Sun, Jingyao Wang, Hengyue Shan, Shengzhe Zhang, Yushan Huang, Yisa Chen, Wenchao Wang, Qingsong Liu, Wenchao Lu, Li Tan, Yi Ding, Jianfei Fu, Jun Long, Lei Zhang, Baobing Zhao, Aibin Liang, Baishan Jiang, Jing Yang   +32 more
wiley   +1 more source

Myeloproliferative neoplasms: a review of diagnostic criteria and clinical aspects [PDF]

, 2010
Chronic myeloproliferative disorders, currently called myeloproliferative neoplasms (MPN), according to the 4th edition of the World Health Organization (WHO) classification are clonal diseases of hematopoietic stem cells, in which there is increased ...
Chauffaille, Maria de Lourdes Lopes Ferrari
core   +1 more source

CALR mutation burden in essential thrombocythemia and disease outcome.

Blood
Among 281 patients with essential thrombocythemia and calreticulin mutation, we found a variant allele frequency of >60% to be associated with significantly shortened myelofibrosis-free survival, mostly apparent with CALR type-1 and CALR type ...
P. Guglielmelli, N. Szuber, N. Gangat, Giulio Capecchi, C. Maccari, M. Harnois, Omer S Karrar, Maymona G. Abdelmagid, M. Balliu, Elena Nacca, A. Atanasio, Ilaria Sestini, Audrey Désilets, G. G. Loscocco, G. Rotunno, Lambert Busque, A. Tefferi, A. Vannucchi   +17 more
semanticscholar   +1 more source

Hemorrhage in Essential Thrombocythemia or Polycythemia Vera: Epidemiology, Location, Risk Factors, and Lessons Learned from the Literature

Thrombosis and Haemostasis, 2020
Hemorrhage is a well-known complication of essential thrombocythemia (ET) and polycythemia vera (PV), but evidence-based data on its management and prevention are lacking to help inform clinicians. In this review, appropriate published data from the past
Christophe Nicol, K. Lacut, B. Pan-Petesch, E. Lippert, J. Ianotto   +4 more
semanticscholar   +1 more source

A Murine Bispecific Antibody Efficiently Redirects T Cells Against Calr Mutated Stem Cells In Vivo

American Journal of Hematology, EarlyView.
ABSTRACT Calreticulin (CALR) mutations are prevalent in 20%–30% of patients with BCR::ABL1‐negative myeloproliferative neoplasms (MPN). Mutant calreticulin (mutCALR), presented by the thrombopoietin receptor (MPL, also known as TPOR or CD110) on the surface of the disease‐initiating MPN progenitors, represents an ideal target for curative ...
Shengen Xiong, Tamara Wais, Cecilia Varga, Christina Schueller, Sarada Achyutuni, Robert Kralovics   +5 more
wiley   +1 more source

Acquired von Willebrand disease as a cause of recurrent mucocutaneous bleeding in primary thrombocythemia: Relationship with platelet count [PDF]

, 1994
We present a 4-year follow-up of a 42-year-old patient with primary thrombocythemia whose clinical course was complicated by two major mucocutaneous bleeding episodes.
Genderen, P.J.J. (Perry) van, Michiels, J.J. (Jan), Poel-van de Luytgaarde, S.C. (Sonja) van der, Vliet, H.H.D.M. (Huib) van   +3 more
core   +1 more source

Modern Approaches to Diagnosis and Treatment of Essential Thrombocythemia: Literature Review and Own Experience

Клиническая онкогематология, 2015
Objective. The aim of our study was to present literature data and own experience about epidemiology, terminology, etiology and pathogenesis of еssential thrombocythemia. Methods.
K. M. Abdulkadyrov, Vasilii Anatol’evich Shuvaev, I. S. Martynkevich   +2 more
doaj   +1 more source